Physician profile
Devendra K Jain
NPI 1083606842
$490.36
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $135 · 2021: $50.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $128.28 | 2019-2020 | |
| Ucb, INC. | $82.43 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $61.38 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $46.01 | 2019 | |
| Amneal Pharmaceuticals LLC | $33.75 | 2019 | |
| Sk Life Science, INC. | $30.25 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $21.72 | 2020 | |
| Acorda Therapeutics, INC | $19.77 | 2019 | |
| Genentech USA, INC. | $18.60 | 2019 | |
| Biogen, INC. | $17.38 | 2020 | |
| Abbvie INC. | $15.93 | 2021 | |
| Adamas Pharmaceuticals, INC. | $14.86 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.